ClinicalTrials.gov
ClinicalTrials.gov Menu

Risk of Urinary Retention With Retigabine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01462656
Recruitment Status : Terminated (This study was halted as the preliminary analysis revealed that the numbers were too low to warrant continuing the project)
First Posted : October 31, 2011
Last Update Posted : November 25, 2016
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

A prospective cohort study of antiepileptic drug (AED) polytherapy-treated epilepsy patients within the HealthCore Integrated Research Database (HIRD) will be conducted. Following the launch of Ezogabine (EZG), patients initiating a new AED polytherapy regimen will be followed until the earliest of an episode of urinary retention (UR), change in their AED regimen, end of follow-up, or end of study (when the specified sample size of EZG AED polytherapy users has been attained). After the end of study, the incidence of UR during exposures to EZG and non-EZG AED polytherapies will be compared. Polytherapy will be defined as treatment regimen containing at least two different AEDs.

A prospective cohort study of patients who receive EZG under circumstances not indicated in the product label within the HIRD will also be conducted. Following the launch of EZG, epilepsy patients initiating AED monotherapy with EZG as well as non-epilepsy patients initiating EZG for another disease will be followed until the earliest of an episode of UR, change in their AED regimen (if applicable), end of follow-up, or end of study. The incidence of UR during exposure to EZG under circumstances not indicated in the product label will be described. A descriptive analysis of the patients will also be included.

To meet the other secondary objective, non-EZG AED monotherapy users will be identified in the prospective cohort and incidence of UR will be calculated to determine if there is a difference in UR risk between monotherapy and polytherapy AED use.


Condition or disease Intervention/treatment
Epilepsy Drug: Non-EZG containing AED polytherapy Drug: EZG containing AED polytherapy Drug: Non-EZG AED monotherapy Drug: EZG AED monotherapy

  Show Detailed Description

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type : Observational
Estimated Enrollment : 1 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Post Marketing Surveillance Study to Monitor the Risk of Urinary Retention in Retigabine Users
Study Start Date : February 2011
Actual Primary Completion Date : August 2016
Actual Study Completion Date : August 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Epilepsy
Drug Information available for: Ezogabine

Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
Patients with urinary retention
Patients with urinary retention
 Drug: Non-EZG containing AED polytherapy
AED polytherapy without EZG

Drug: EZG containing AED polytherapy
AED polytherapy including EZG

Drug: Non-EZG AED monotherapy
AED monotherapy without EZG

Drug: EZG AED monotherapy
Any off-label use of EZG as monotherapy


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. The risk and time to onset of UR associated with post-marketing use of EZG AED polytherapy, and the incremental risk compared with non-EZG AED polytherapy use. [ Time Frame: From initiation of a new AED polytherapy regimen, until the earliest of an episode of UR, change in their AED regimen, end of follow-up, or end of study, whichever comes first, assesed up to three years. ]

Secondary Outcome Measures :
  1. The risk and time to onset of UR among patients using EZG vs. non-EZG AED polytherapy [ Time Frame: From initiation of a new AED polytherapy regimen, until the earliest of an episode of UR, change in their AED regimen, end of follow-up, or end of study, whichever comes first, assesed up to three years. ]
  2. The risk of UR associated with post-marketing use of EZG under circumstances not indicated in the product label [ Time Frame: From initiation of a new AED polytherapy regimen, until the earliest of an episode of UR, change in their AED regimen, end of follow-up, or end of study, whichever comes first, assesed up to three years. ]
  3. The risk of UR among non-EZG AED monotherapy patients and the differential risk in UR for monotherapy versus polytherapy-treated patients [ Time Frame: From initiation of a new AED monotherapy regimen, until the earliest of an episode of UR, change in their AED regimen, end of follow-up, or end of study, whichever comes first, assesed up to three years. ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The study cohorts of interest will be identified from the HealthCore Integrated Research Database (HIRD). The HIRD contains fully adjudicated paid claims from the largest commercially insured population in the US, with dates of service for all non-capitated ambulatory, emergency department, inpatient, and outpatient encounters (including administrative claims for laboratory tests) for members with eligibility at the time of service.
Criteria

Inclusion Criteria:

  • Prospective Cohort (indicated use)

    • Patients with at least one medical claim carrying an ICD-9 code for epilepsy. The following ICD-9 codes will be used to identify patients with epilepsy:

      • 345 Epilepsy and recurrent seizures
      • 780.3 Convulsions
      • 780.39 Other convulsions
    • Patients initiating a new AED monotherapy* or polytherapy** following the launch of EZG.
    • At least 6 months of continuous healthcare plan enrolment before initiation of the new AED (monotherapy or polytherapy) following the launch of EZG. This will allow an assessment of baseline co-morbidities and concomitant medication use.
    • Aged ≥18 years at initiation of the new AED (monotherapy or polytherapy).

  • Prospective Cohort (non-indicated use)

    • Epilepsy patients initiating EZG AED monotherapy
    • Patients <18 years old initiating EZG for epilepsy
    • Patients initiating EZG for any reason other than epilepsy
    • Patients initiating EZG AED polytherapy with less than six months of continuous healthcare enrolment who were excluded from the cohort described under the primary objective

  • Retrospective Cohort

    • Patients with at least one medical claim carrying an ICD-9 code for epilepsy in the three year period preceding the launch of EZG. The following ICD-9 codes will be used to identify patients with epilepsy:

      • 345 Epilepsy and recurrent seizures
      • 780.3 Convulsions
      • 780.39 Other convulsions
    • Patients initiating a new AED monotherapy* or polytherapy** regimen in the three year period preceding the launch of EZG.
    • At least 6 months of continuous healthcare plan enrolment before initiation of the new AED regimen (monotherapy or polytherapy) during the three year period preceding the launch of EZG. This will allow an assessment of baseline co-morbidities and concomitant medication use.

    • Aged ≥18 years at initiation of the new AED (monotherapy or polytherapy).

      • This will include patients substituting an AED monotherapy. **This will include patients switching from a monotherapy to polytherapy regimen and those substituting an AED within an existing polytherapy regimen.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01462656


Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT01462656     History of Changes
Other Study ID Numbers: 115981
WEUKSTV4551 ( Other Identifier: GSK )
EPI40621 ( Other Identifier: GSK )
First Posted: October 31, 2011    Key Record Dates
Last Update Posted: November 25, 2016
Last Verified: November 2016

Keywords provided by GlaxoSmithKline:
anti-epileptic drug
ezogabine
AED polytherapy
epilepsy
 AED monotherapy
retigabine
urinary retention

Additional relevant MeSH terms:
Epilepsy
Urinary Retention
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Urination Disorders
 Urologic Diseases
Ezogabine
Anticonvulsants
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action